See the latest news and media coverage for Aethlon Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical device developer for cancer and viral infections
aethlonmedical.comLast updated
In short: Aethlon Medical progressed oncology trials, completed a $4 million public offering, and reported significant reductions in expenses.
The company reports $4.9 million in cash, a $4.0 million public stock offering after the quarter, an 11.9% decrease in operating expenses, and Phase 1 oncology trial advancements alongside accepted Long COVID research.
The company advanced its Australian oncology trial into the final dosing cohort, secured new patents for Long COVID applications, and reduced operating expenses by nearly twenty-two percent compared to the previous fiscal year.
Management will host a conference call on June 10, 2026, to review the March 31 financials and discuss recent corporate developments.
The clinical-stage medical device company will work with the financial advisor to explore potential mergers, acquisitions, and partnerships following preliminary market interest.
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results...
Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier...
James Frakes: Thank you, operator, and good afternoon, everyone. My name is Jim Frakes, and I'm the Chief Executive Officer and Chief Financial Officer...
Aethlon Medical, Inc. Q3 2026 Earnings Call Summary - Moby Strategic Execution and Platform Expansion Progress in the Australian oncology trial is driven...
Track Aethlon Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.